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Abstract 
Drug resistance is still a major challenge in cancer therapy. Drug combination is expected to 
overcome drug resistance. However, the number of possible drug combinations is enormous, and 
thus it is infeasible to experimentally screen all effective drug combinations considering the limited 
resources. Therefore, computational models to predict and prioritize effective drug combinations 
is important for combinatory therapy discovery in cancer. In this study, we proposed a novel deep 
learning model, AuDNNsynergy, to prediction drug combinations by integrating multi-omics data 
and chemical structure data. In specific, three autoencoders were trained using the gene 
expression, copy number and genetic mutation data of all tumor samples from The Cancer 
Genome Atlas. Then the physicochemical properties of drugs combined with the output of the 
three autoencoders, characterizing the individual cancer cell-lines, were used as the input of a 
deep neural network that predicts the synergy value of given pair-wise drug combinations against 
the specific cancer cell-lines. The comparison results showed the proposed AuDNNsynergy 
model outperforms four state-of-art approaches, namely DeepSynergy, Gradient Boosting 
Machines, Random Forests, and Elastic Nets. Moreover, we conducted the interpretation analysis 
of the deep learning model to investigate potential vital genetic predictors and the underlying 
mechanism of synergistic drug combinations on specific cancer cell-lines. 
 
 
 
 
 
1.Introduction 
Combinatory therapies are being adopted in treating complicated diseases, e.g., cancer [1] and 
AIDS [2], which are more effective with reduced toxicity, and can overcome intrinsic or acquired 
resistance to individual drugs [3]. Generally, there are three types of pair-wise drug combination 
interactions: additive interaction (the effect (e.g., tumor cell growth inhibition) of a drug 
combination is equal to the sum of effects of individual drugs taken separately), synergistic 
interaction (the effect of a drug combination at specific doses is greater than the sum of effects of 
individual drugs) and antagonistic interaction (the effect of a drug combination is less than the 
sum of effects of individual drugs). A few synergistic drug combinations have been discovered, 
for example, targeted therapy and  immune treatment [4], targeted therapy and targeted therapy 
[5], targeted therapy and chemotherapy combinations [6]. Also mechanisms of synergy of drug 
combinations are diverse and distinct, for example, two drugs can achieve synergy by targeting 
different oncogenic pathways or mutations simultaneously [7], [8].  
 It is a challenging task to experimentally screen drug combinations considering the 
enormous number of possible combinations and heterogeneous mechanisms of synergy. 
Therefore, computational models to predict effective drug combinations for specific cancer 
subtypes or individual patients is important and urgently needed. To facilitate the development of 
computational models of drug combinations, more and more datasets of drug combinations have 
been being generated. For example, 178 drug combinations were collected from FDA orange 
book by Zhao et al. [9], and  239 drug combinations were derived from literature curated by Huang 
et al. [10]. The DCDB database [11] has 1363 drug combinations, and the ASDCD database [12] 
has 210 drug combinations. Moreover, experimental screening of combinations of 39 drugs 
against 38 cell lines were reported in [13]; and screening results of combinations of 104 drugs 
against 59 cell lines were reported in [14].  
In spite of the existing approaches, drug combination prediction is still an open problem. 
For example, Li et al. [15] developed a network propagation method to predict drug synergy based 
on the gene-gene interaction network. Janizek et al. [16] used XGBoost method combing with a 
tool named TreeSHAP to predict and make prediction results explainable. A system biology 
method was designed by Feala et al. [17]; Nelander et al. [18] built a nonlinear multiple‐input, 
multiple‐output network model. Chen et al. [19] predicting potential combinations based on semi-
supervised learning. Also some computational models [20],[21],[22] have been proposed 
integrating the genomics profiles of tumor and reverse gene signatures of drugs derived from 
connective map database [23],[24]. Deep learning models have been developed to solve medical 
problems and outperformed the traditional machine learning methods. For example, Preuer et al. 
[25] proposed a deep neural network (DNN) model named DeepSynergy with an improvement of 
7.2% over Gradient Boosting Machines for synergy task. Chiu, Y. C et al. [26] created a model 
using DNN to predict single drug response of tumors. Gao et al. [27] predicted drug target using 
a recurrent neural network and convolution neural network. However, the large number of features 
used in deep learning models might cause overfitting problem. Also, most models were trained 
using the genomics data of a small number of cancer cell-lines, and it is hard to generalize the 
model to new cancer cell lines or patients. Moreover, most deep learning models were not 
explained, and it is hard to understand the potential mechanism of synergy of drug combinations.  
To improve the prediction accuracy and explain the deep learning models (black box), in 
this study, we proposed a novel model, AuDNNsynergy (Deep Neural Network Synergy model 
with Autoencoders), for synergistic drug combination prediction. The comparison results 
indicated that the AuDNNsynergy model outperformed four state-of-art approaches in ten model 
measurements. In this model, multi-omics datasets, i.e., gene expression, mutation, copy number 
variation, and physicochemical properties of drugs were integrated to achieve better prediction 
accuracy. Moreover, to make the model has prediction ability for unseen cell lines and tumors, 
we trained autoencoders with all tumor samples form The Cancer Genome Atlas (TCGA) (pan-
cancer dataset). Also, we used a particular cross-validation technique to select the best 
hyperparameters for the deep learning model. Finally, we conducted the interpretation analysis 
of the deep learning model to discover potential driver genetic features and uncover underlying 
mechanisms of synergistic drug combinations.  
 
2. Materials  
2.1 Data 
Drug combination screening dataset. The high-throughput drug combination screening dataset 
was downloaded from [13]. In specific, 583 pairwise drug combinations of 38 individual drugs 
were screened against 39 human cancer cell lines. The 39 cell lines include seven types of 
cancers, i.e., lung, breast, skin, large intestine, pleura, prostate, and ovary. Tumor cell viability 
after 48 hours of drug treatments (4 doses for each drug) were measured to estimate the synergy 
of drug combinations. In total, there are 23062 data points. 
Omics data of cancer cell lines and TCGA samples. RNA-seq data of the 1156 cancer cell 
lines and 10,535 tumor samples from The Cancer Genome Atlas (TCGA) were downloaded from 
Cancer Cell Line Encyclopedia (CCLE) and UCSC Xena Server [28] (URL: 
https://xenabrowser.net/datapages/?dataset). The somatic mutation data of the screened cell 
lines and 9104 TCGA tumor samples were downloaded from Catalogue of Somatic Mutations in 
Cancer (COSMIC) [29] and UCSC Xena  respectively. The copy number of 10,845 TCGA pan-
cancer tumors and the 39 cancer cell lines can be accessed from UCSC Xena and CCLE 
respectively. Some cancer cell lines data cannot be found in CCLE, and COSMIC. We used the 
genomics data of EFM-129A and COLO320 for the EFM-129B and COLO320DM cell lines 
respectively. In brief, the EFM-129B established from the same person of EFM-129A after 14 
days. The COLO320DM is children of COLO320. 
 
Physicochemical features of drugs. To characterize the chemical structures of individual drugs, 
we used the counts of extended connectivity fingerprints with a radius of 6 (ECP_6) [30], 
predefined physicochemical properties and presence or absence of toxicophores substructures, 
which were obtained by using jCompoundMapper [31] and Chemopy [32] respectively. 
 
2.2 Data pre-processing 
The gene expression data was normalized as log2(𝑡𝑝𝑚 + 0.001), where 𝑡𝑝𝑚 denotes the number 
of transcripts per million. The mutation data (only non-silent mutations were used) was formalized 
as a binary variable: 1 (with mutation) and 0 (no mutation). Copy number variation (CNV) were 
estimated using GISTIC2 method [33]. For synergy score of drug combinations, the Loewe 
Additivity model was used[34]. All features were filtered by removing elements with zero variance 
and then normalized to has zero-mean and unit variance. We denote 𝐸𝑇 , 𝐸𝐶 , 𝑀𝑇 , 𝑀𝐶 , 𝐶𝑇  as 
processed data, where 𝐸, 𝑀, and 𝐶 represent gene expression, mutation, copy number and drug, 
and the T and C indicate tumor and cell lines. For example, 𝐸𝑇 presenting TCGA expression data 
after pre-processing. After preprocessing, each cell line contains 50196, 17643 and 20318 
features of expression, mutation, and copy number, and each drug represented using the 2431 
physicochemical features, denoted by D. In total, each drug combination against a given cancer 
cell line has 93019 features.  
 
3. Model 
3.1 Architecture of AuDNNsynergy 
The AuDNNsynergy model consists of two major components: three autoencoders and a deep 
neural network, as shown in  
 
Figure 1.  
Settings of autoencoders. The three autoencoders are the expression autoencoder (𝐸𝑛𝑒𝑥 ), 
mutation autoencoder (𝐸𝑛𝑚𝑢) and copy number autoencoder (𝐸𝑛𝑐𝑜), which were trained using 
TCGA multi-omics data to transfer the knowledge embedded in the large-scale genomics data of 
TCGA samples. The cell lines’ gene expression, copy number and mutation data are then 
encoded using the trained three autoencoders, and the outputs are used as the input of the 
prediction network. In specific, we applied six densely connected layers neural network structure 
for each autoencoder. Moreover, to choose the optimal autoencoder structures and parameters, 
the number of neurons and batch size were set as hyperparameters, which result in 20 
alternatives of autoencoders. The shape of layers is conic and symmetry with five hidden layers 
have the number of neurons selected from [8192, 4096, 2048, 1024, 512], and the batch size 
selected from [512, 256]. The linear activations were used in the output layer and bottleneck layer, 
and the rectified linear activations were used for other layers. The minimum square error (MSE) 
was used as the cost function minimized by Adam optimizer with default learning rate. The He’s 
uniform distribution was used for initialization, and a moving average over five epochs on a 
validation set early-stopping was used for training iterations. 
Settings of the deep neural network. The shape of layers is conic. The number of layers, the 
number of neurons and learning rate were set as hyperparameters. The number of layers was 
selected from [2,3], the number of neurons was selected from [8192, 4096, 2048, 1024, 512]; and 
the number of learning rate was selected from [10−1, 10−3, 10−5]. The linear activations were 
used in the output layer, and rectified linear activations were used in the hidden layers. The batch 
size of 64, a dropout rate of 0.2 and 0.5 for the input and hidden layers, and stochastic gradient 
descent optimizer with momentum 0.5 to minimizes MSE cost function were used. The He’s 
uniform distribution was used for initialization, and a moving average over 15 epochs on a 
validation set early-stopping was used for training iterations. Mathematically, the output 𝒂𝑖 of layer 
𝑖 is calculated by 𝒂𝑖 = 𝑨𝑖(𝑾𝑖𝒂𝑖−1 + 𝒃𝑖), where 𝒂𝑖 denotes the production of layer i (𝒂0 is the input), 
𝑨𝑖, 𝑾𝑖and 𝒃𝑖 are the activation function, weight matrix and bias vector of layer 𝑖 respectively. The 
weights and biases are learned by backpropagation to minimizes the MSE cost function. 
 
3.2 Cross-validation and model interpretation analysis 
For autoencoders’ training, each omics data was randomly split into training (90%) and testing 
(10%) data, and this training was repeated 5 times. For the prediction network, we used five-fold 
cross-validation experiments to estimate the performance of AuDNNsynergy. To make the model 
robust each drug-drug combination only appeared in one of these five folds. We used one fold of 
training dataset as validation dataset to tune the model. To interpret the deep learning model, the 
‘Innvestigate’ package [35] was used to analyze networks’ predictions to investigate importance 
of features. The method of pixel-wise explanations by layer-wise relevance propagation (LRP)  
[36] was adopted. In specific, we used Innvestigate first to get the important drug and encoded 
genomic features contributing to the synergy score; and then we used LPR again to the interesting 
genomic features for the selected encoded nodes of encoders outputs.  
 
3.3 Computation environment of AuDNNsynergy 
We deployed the model on Google Cloud Platform with system Ubuntu 16.04, four vcpu, 32G 
memory, and NVIDIA Tesla V100 GPU. The AuDNNsynergy was run under CUDA 9.0, cuDNN 
9.0 using Keras 2.1 with GPU supporting Tensorflow 1.4 backend.  
 
3.4 Model comparison 
We compared AuDNNsynergy with four state-of-arts machine learning models, including 
DeepSynergy [25], Gradient Boosting Machines [37], Random Forests [38], and Elastic Nets [39]. 
We evaluated these model, except DeepSynergy, on the 8846 features dataset [25] and on the 
93019 features dataset constructed in this study. The DeepSynergy model was only evaluated on 
the 8846 features dataset. The reason is that the memory of NVIDIA Tesla V100 GPU is not 
enough to train it using the 93019 features dataset, which is a limitation of DeepSynergy. To 
evaluate the DeepSynergy model (a three-layer deep neural network), top 3 hyperparameter 
settings of performance were used. For the gradient boosting ensembles model, the number of 
trees and number of features in each split were set as hyperparameters. Random decision forests 
are also an ensemble machine learning method operated by constructing a multitude of decision 
trees. Different numbers of trees and numbers of features in each split were evaluated. The Elastic 
Net is a regularized regression method with a linear combination of lasso and ridge as a penalty 
of sparse constraint. We performed it with different 𝛼 values and 𝐿1 ratio that controls the relative 
weights of 𝐿1 and 𝐿2. The hyperparameter settings of these four methods can be found in Table 
1. 
 
4. Results 
4.1 Synergistic drug combination prediction 
The 𝐸𝑛𝑒𝑥  autoencoder with 8192, 2048 and 512 neurons in three layers respectively, and batch 
size 256; The 𝐸𝑛𝑒𝑥  autoencoder with 8192, 2048 and 1024 neurons in three layers respectively 
and batch size 256, and the 𝐸𝑛𝑒𝑥  autoencoder has 8192, 2048 and 1024 neurons in three layers 
and batch size 256, have the best performance. The two-layers deep neuron network with 8192 
and 2048 neurons respectively and 10−5  learning rate has the best performance. The 
performance of the models was measured using the rank correlation and MSE measurements 
between the experimental synergy scores and the predicted synergy scores. The rank correlation 
coefficient measures the rank correlation for sometimes predicting priorities of drug pairs is more 
important than accurately predicting the sensitivity to all potential drugs, and MSE is commonly 
used to assess the quality of an estimator. The prediction results, in terms of rank correlation and 
MSE, of the proposed AuDNNsynergy model are shown in Figures 2, 3, 4 and 5. As can be 
seen, the prediction accuracy varies significantly among cell lines and drugs, which might be 
caused by the distinct mechanisms of different drug-drug pair synergistic/antagonistic effects on 
specific cell lines. For individual cell lines, the rank correlation coefficients vary from 0.56 to 0.81. 
Only three cell lines exhibit a correlation below 0.6, and >55% of the cell lines can be predicted 
with a correlation >0.7. The MSE varies in the range of 61 to 526. Similarly, only three cell lines 
have MSEs >400; and 50% of the cell lines have MSE < 0.7. For individual drugs, the rank 
correlation coefficients fall in the range of 0.55 to 0.86. Only two drugs have rank correlation 
coefficients below 0.6; and ~67% of the drugs have rank correlation coefficients higher than 0.7. 
The MSEs for drugs vary from 64 to 846. Three drugs have MSEs larger than 400; and ~ 67% of 
the drugs have MSEs lower than 200. Specifically, the Sunitinib and Doxorubicin are relatively 
easy to predict, with rank correlation values above 0.7 and MSE below 100. Moreover, we ranked 
observed synergy scores and compared with the drug pairs with the highest predicted scores. For 
over 93% test cell lines, the most synergistic drug pair predicted by AuDNNsynergy falls in the 
top 5 synergistic drug combinations based on the experimental data. For over 74% cell lines, the 
model correctly predicted the most synergy pairs. We summarized this result using the pie chart, 
as shown in Figure 6. 
We also investigated the poor predictions, which is defined as the difference between 
prediction synergy value and experimental value is over 100. There are 51 samples (2‰ of all 
data points) in total, and 10 of them are from the LNCAP (prostate adenocarcinoma) cell line; 9 
of them are from the NCIH2122 (lung cancer) cell line; and 12 of them are from the NCIH23 cell 
line. For drugs, the combinations of MK-4827, GELDANAMYCIN and MK-8776, BEZ-235 appear 
most frequently with six times in the poor predictions. In summary, most of the predictions are 
good, as shown in the scattering plot in Figure 7. 
 
4.2 Model comparison 
The detailed model comparison results are listed in Table 2 and Table 3, using the measurements 
of rank correlation, MSE, confidence interval, root mean square error (RMSE) and Pearson 
correlation. The models were evaluated on the 93019 features dataset, and the 8846 features 
dataset (*marked). As can be seen, the proposed AuDNNsynergy model outperforms other four 
models, especially in terms of the rank correlation (0.73) and MSE (241.12). Moreover, it can be 
seen that other models could not improve their performance even using more features. Also, it is 
hard to apply the DeepSynergy directly on the 93019 features dataset because there will be more 
than six hundred million parameters to be optimized. Therefore, it cannot be run on the google 
cloud platform. Table 3 shows the area under the receiver operator characteristics curve (ROC 
AUC), area under the precision-recall curve (PR AUC), accuracy (ACC), precision (PREC) and 
Cohen's Kappa of the five models. The proposed AuDNNsynergy model has the best performance 
in terms of ROC AUC, PR AUC, ACC, PREC and Kappa compared with other models. 
 
5. Interpretation analysis 
5.1 Important omic features for the overall prediction 
Using the interpretation analysis, the number of most important features that can negatively 
regulate, positively regulate and impact the model are listed in Table 4, Table 5, and Table 6, 
respectively. As can be seen, over 50% of most important features are the chemical structures. It 
is interestingly that the number of important omics features almost will not change with more 
feature selected. To identify the important genes, we employ the interpretation analysis twice. 
First, we used the interpretation analysis to get the encoded omics features in the top 100 
important features; and repeat five times to select the common features. Then we conduct the 
interpretation analysis again on the autoencoders to identify the related genes. In summary, the 
gene expression of 2 genes, mutation of 25 genes, and copy number of 14 genes were selected, 
which are listed in Table 7. Through the literature review, we found that many of these genes 
have been reported related to drug resistance or sensitivity, e.g., STAT3, miR-222, XIAP, FGF16, 
PBRM1, and SPP1. For example, the feedback activation of STAT3 is a common cause of 
resistance to many targeted cancer therapies and chemotherapies [40]. The miR-222 confers 
Adriamycin and Docetaxel resistance in MCF-7 cells [41]. The FGF16 gene regulates 
aggressiveness of HepG2 and PLC/PRF/5 cells [42]. The mutation of PBRM1, a subunit of the 
SWI/SNF complex, attenuated the effect of Gefitinib in part by sustaining AKT pathway function 
during EGFR inhibition [43]. The SPP1 gene plays an important role in drug sensitivity of 
malignant pleural mesothelioma [44], Oral Squamous Cell Carcinoma [45], and pancreatic cancer 
[46]. SPP1 is also pivotal in tumor cell proliferation, angiogenesis and metastasis in ovarian [47], 
brain [48], lung [49], kidney [50], liver [51], bladder [52], breast [53], esophageal [54], gastric [55], 
colon [56] and prostate cancers [57]. 
 
5.2 Mechanism of synergy for specific drug combinations against given cell lines 
We also explored underlying mechanisms of synergy of some drug combinations. For example, 
Dasatinib and Carboplatin have synergy effect on ovarian cell line A2780 [58]. Dasatinib targets 
the SRC while carboplatin targets the DNA. We found the most important gene is the copy number 
of PTPRK, which dephosphorylates SRC [59]; Drug combination Sorafenib and Erlotinib are 
reported to treat non-small cell lung cancer (NSCLC) [60]. Erlotinib and Sorafenib are the 
inhibitors of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor 
(VEGF) receptor respectively. The two of the most important omics predictors of this response 
are gene PAIP2 and gene miR-507. PAIP2 has a positive effect on the response while miR-507 
has an adverse effect. Suppressing miR-507 promotes VEGF-C production [61], and PAIP2 is a 
strong regulator of VEGF [62]. However, the PAIP2, miR-507, and PTPRK gene are not in the 
most critical predictors for all drug combination predictions. The results indicate that the 
interpretation analysis could be useful for uncovering novel mechanism of synergy for specific 
drug combination against given cancer cell-lines.  
 
5.3 Synergistic drug combination prediction for TCGA samples 
We also applied the AuDNNsynergy to predict synergy score of the 853 drug combinations on 
TCGA samples. Although the omics profiles of cell lines and tumors might be different, some 
prediction results are still meaningful. For example, drug combination Dasatinib/Erlotinib has a 
high synergy score (rank 7/583) for the NSCLC bears EGFR mutation. Dasatinib is an inhibitor of 
SRC while Erlotinib is EGFR inhibitor and this pair has been reported are synergy, safe and 
feasible in NSCLC with activating EGFR mutations [63]. Also, the Dasatinib with another EGFR 
inhibitor, Laptinib, have a high synergy score (rank 5/583) for NSCLC with EGFR mutation. The 
other example is the ABT-888/BEZ-235, MK-4827/BEZ-235, and MK4827/MK8669 combinations, 
which are top ranked in our prediction (top 4%-7%). ABT-888 and MK-4827 target on PARP while 
BEZ-235 and MK-8669 target on MTOR on breast cancer samples. The literature review [64] 
showed that the treatment of a BRCA2 mutated luminal breast cancer PDX by Everolimus and 
Olaparib combination resulted in tumor regression. Interestingly, Olaparib is a PARP inhibitor 
while Everolimus is a mTOR inhibitor, and their combination could lead to unrepaired DNA 
damage and tumor regression in vivo, through a cross-talk between DNA repair and mTOR 
pathways. These promising examples show that the proposed model can be used to predict drug 
combinations for new tumor samples not in the 39 cell lines in the screening data. One of the 
reasons is that the proposed AuDNNsynergy model is trained using the TCGA samples, and it 
can transfer and maintain the knowledge of different tumor samples to achieve robust predictions 
for new tumor samples. 
 6. Discussion 
In this study, we have presented a deep learning model, AuDNNsynergy, which outperforms 
existing models of drug combination prediction. In the model, we integrated multi-type of 
genomics data, e.g., gene expression, copy number and mutation using three autoencoders; and 
applied the transfer learning to train the autoencoders using TCGA data. The results indicated 
that the transfer learning of TCGA data can improve the prediction accuracy. Also, we conducted 
the interpretation analysis, and identified a set of interesting omics features for drug combination 
prediction, and uncovered potential mechanisms of synergy of specific drug combination against 
given cancer cell lines. 
 In the future work, we aim to improve the performance of AuDNNsynergy as follows. 1) A 
larger drug combination screening dataset will be used to evaluate the AuDNNsynergy model. 
There are a few drug combination datasets reported. However, the measurements of drug 
combination synergy are heterogeneous. We will merge these screening datasets using a 
standard measurement of combinations effectiveness to evaluate the AuDNNsynergy model. 2) 
More types of genomics data, e.g., methylation, PARADIGM pathway activity, protein expression, 
and drug structure graph can be added to improve the prediction model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Hyperparameter settings of 4 method. 
 
 
 
 
 
 
 
 
Table 2. Rank Correlation, MSE, Confidence Interval, RMSE and Pearson correlation for 5 methods on the 
93019 features dataset, and the 8846 features dataset (*marked). 
 
 
 
 
 
 
Method Hyperparameter 
Deep Synergy 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 ℎ𝑖𝑑𝑑𝑒𝑛 𝑙𝑎𝑦𝑒𝑟𝑠 𝑛𝑒𝑢𝑟𝑜𝑛𝑠 ∈ {[8192,4096], [8192,8192], [8192,2048]} 
Gradient Boosting 
Machines 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑜𝑟𝑠 ∈ [128,256,512,1024] 
𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠 𝑐𝑜𝑛𝑠𝑖𝑑𝑒𝑟𝑒𝑑 ∈ [𝑙𝑜𝑔2(# 𝑜𝑓 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠), 𝑠𝑞𝑢𝑎𝑟𝑒(# 𝑜𝑓 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠)] 
 
Random Forests 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑜𝑟𝑠 ∈ [128,256,512,1024] 
𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠 𝑐𝑜𝑛𝑠𝑖𝑑𝑒𝑟𝑒𝑑 ∈ [𝑙𝑜𝑔2(# 𝑜𝑓 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠), 𝑠𝑞𝑢𝑎𝑟𝑒(# 𝑜𝑓 𝑓𝑒𝑎𝑡𝑢𝑟𝑒𝑠)] 
Elastic Nets 
𝛼 ∈ [0.1, 1,10,100] 
𝐿1 𝑟𝑎𝑡𝑖𝑜 ∈ [0.25,0.5,0.75] 
Method 
Rank 
Correlation 
MSE RMSE Pearson correlation  
AuDNNsynergy 0.730.02 241.1243.52 15.461.44 0.740.03 
Deep Synergy* 0.660.02 255.4949.54 15.911.56 0.730.04 
Gradient Boosting Machines 0.640.02 310.7350.40 17.571.42 0.640.02 
Gradient Boosting Machines* 0.640.01 308.0649.34 17.501.39 0.640.02 
Random Forests 0.640.02 326.3153.54 18.001.45 0.630.02 
Random Forests* 0.630.02 330.1851.45 18.121.37 0.610.03 
Elastic Nets 0.490.02 422.7254.35 20.521.30 0.440.02 
Elastic Nets* 0.490.02 424.3854.39 20.561.30 0.440.02 
 
 
Table 3. ROC AUC, PR AUC, ACC, PREC and Kappa for 5 methods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. The number of 4 types features of most positive effect for synergy scores. 
 
 
 
Table 5. The number of 4 types features of most negative effect for synergy scores. 
 
Performance Metric ROC AUC PR AUC ACC PREC Kappa 
AuDNNsynergy 0.910.02 0.630.06 0.930.01 0.720.06 0.510.04 
Gradient Boosting 
Machines 
0.870.02 0.540.04 0.930.01 0.720.03 0.390.05 
Random Forests 0.860.03 0.510.04 0.920.02 0.570.04 0.210.04 
Elastic Nets 0.770.04 0.330.09 0.920.01 0.230.29 0.150.09 
Deep Synergy* 0.900.03 0.590.06 0.920.03 0.560.11 0.510.04 
Features 100 500 1000 2000 
Expression 0.20.4 0.20.4 0.20.4 0.20.4 
Mutation 9.40.5 9.60.8 9.81.2 10.60.8 
Copy Number 11.22.0 12.22.3 12.42.2 12.62.1 
Drug 79.21.6 478.01.8 977.61.3 1976.61.2 
Features 100 500 1000 2000 
Expression 1.80.4 1.80.4 1.80.4 4.65.2 
Mutation 11.80.4 12.20.7 12.20.7 36.248.4 
Copy Number 13.21.7 13.41.9 13.62.2 143.897.0 
Drug 73.21.2 472.61.5 972.41.6 1820.875.1 
 
 
 
 
 
 
 
 
 
 
Table 6. The number of 4 types features effect synergy scores most. 
 
 
 
 
 
 
 
 
Table 7. Important genomic features.  
 
Feature type Gene symbol 
Expression miR-222, STAT3 
Mutation 
HYDIN, MUC19, DNAH3, TBCE, MDN1, KIF21B, SHARPIN, 
RIBC2, NEB, USP53, USP35, SPP1, PCDH1, KLF5, 
ANK3, CMTM1, PPL, STK32B, C21orf67, LRP1B, DMD, 
AIM2, NAA60, XRCC6BP1, PPFIA2 
Copy number 
PRPF39, SNORD22, PBRM1, SNORA68, SCARNA14, SNORD23, MIRLET7G, 
SNORA77, INO80D, XIAP, CNOT10, FGF16, LCTL, SNORA43 
 
Features 100 500 1000 2000 
Expression 2.00.0 2.00.0 2.00.0 2.00.0 
Mutation 20.80.4 21.40.5 21.80.7 22.20.4 
Copy Number 24.20.7 25.20.7 25.40.8 25.80.4 
Drug 52.80.4 451.41.0 950.81.2 1950.00.0 
 
 
 
Figure 1. Overview of the AuDNNsynergy architecture. 
 
 
Figure 2. MSE of predicted synergy scores per cell line. 
 
 
Figure 3. Rank correlation coefficients between observed and predicted synergy scores per cell line. 
 
 
Figure 4. MSE of predicted synergy scores per drug. 
 
 
Figure 5. Rank correlation coefficients between observed and predicted synergy scores per drug. 
 
 
 
Figure 6. Ranking correlation between prediction and experimental validations. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. The overall distribution of predicted and the experimental validated synergy scores. 
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